临床案例 / 真实世界数据
吾谷灵™五谷虫辅助治疗肺恶性肿瘤术后验案一则
关键数据一览
35.3U/mL
CA125 糖类抗原
明显回落
术前 64.2 → 35.3
↓
肺部结节影
减少清晰
胸腔积液吸收
患者基本情况
陈女士，女，49岁，肺恶性肿瘤术后。2023年11月开始服用吾谷灵™五谷虫，每日三次，每次3-9粒。
服用前后总结
肺部情况：术后及服药期间肺部结节影减少、边缘清晰，胸腔积液减少，微结节长径缩小，整体趋于稳定。
血液指标：术前 CA125 显著升高（64.2 U/mL）；服药期间降至 34.5-35.3 U/mL，其他肿瘤标志物趋于正常。
总体评估
患者肺部情况与肿瘤标志物均有所改善，总体健康状态趋于稳定。建议继续服用并定期复查。
个案仅供参考，不构成医疗建议。
医学报告与数据
重要声明：本页面为吾谷灵™五谷虫真实世界辅助调理个案整理，仅供学术交流参考，不构成医疗建议，不能替代手术、放疗、化疗等标准抗肿瘤治疗。个案结果因人而异，具体用药请遵医嘱。
Clinical Cases / Real-world Data
Vogreen Medicinal Housefly Larvae Adjuvant Treatment of Postoperative Lung Malignancy
Key Data Overview
35.3U/mL
CA125 Carbohydrate Antigen
Marked decline
Pre-op 64.2 → 35.3
↓
Lung Nodules
Reduced & clearer
Pleural effusion absorbed
Case Summary
A 49-year-old female with postoperative lung malignancy took Vogreen Medicinal Housefly Larvae from November 2023. Follow-up showed fewer lung nodules with clearer margins, absorbed pleural effusion, and CA125 reduced from 64.2 to 35.3 U/mL. Overall condition stabilized. Recommended to continue with regular chest CT and blood monitoring. For reference only, not medical advice.
Key Data & Reports
Please refer to the medical reports and data charts below for detailed examination results and imaging records.
Medical Reports & Data
Disclaimer: This page documents a real-world adjuvant care case of Vogreen Medicinal Housefly Larvae for academic exchange only. It does not constitute medical advice and cannot replace standard anti-tumor treatments such as surgery, radiotherapy or chemotherapy. Individual results vary. Please follow your physician's guidance.